P-137 * HIGH-QUALITY SECRETOME OF A549 CELLS AIDED THE DISCOVERY OF C4B-BINDING PROTEIN AS A NOVEL SERUM BIOMARKER FOR NON-SMALL-CELL LUNG CANCER

X. Luo,Y. Liu,R. Wang,H. Hu,Y. Pan,L. Wang,T. Ye,Y. Zhang,H. Li,Z. Sun,D. Cai,Y. Sun,R. Zeng,H. Chen

DOI: https://doi.org/10.1093/icvts/ivu167.137

2014-01-01

Interactive Cardiovascular and Thoracic Surgery

Abstract:Objectives: Cancer secretomes are a promising source for biomarker discovery. The analysis of cancer secretomes still faces some difficulties mainly related to the intracellular contamination, which hinders the qualification and follow-up validations. This study aimed to establish a high-quality secretome of A549 cells by using the cellular proteome as a reference and to test the merits of this refined secretome for biomarker discovery for non-small-cell lung cancer (NSCLC). Methods: Using one-dimensional gel electrophoresis followed by liquid-chromatography tandem mass spectrometry, we comprehensively investigated the secretome and the concurrent cellular proteome of A549 cells. Results: A high-quality secretome consisting of 382 proteins was refined from 889 initial secretory proteins. More than 85.3% of proteins were annotated as secreted and 76.8% as extracellular or membrane-bound. The discriminative power of the lung-cancer associated secretome was confirmed by gene expression and serum proteomic data. The elevated level of C4b-binding protein (C4BP) in NSCLC blood was verified by enzyme-linked immunosorbent assays (ELISA, P = 6.07e-6). Moreover, the serum C4BP level in 89 patients showed a strong association with the clinical staging of NSCLC. Conclusions: Our reference-experiment-driven strategy is simple and widely applicable, and may facilitate the identification of novel promising biomarkers of lung cancer. Disclosure: No significant relationships.